These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 6428806)

  • 21. Pharmacokinetic and pharmacodynamic investigations with vaginal devices releasing levonorgestrel at a constant, near zero order rate.
    Landgren BM; Johannisson E; Masironi B; Diczfalusy E
    Contraception; 1982 Dec; 26(6):567-85. PubMed ID: 6820337
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patterns of ovulation and bleeding with a low levonorgestrel-releasing intrauterine device.
    Nilsson CG; Lähteenmäki P; Luukkainen T
    Contraception; 1980 Feb; 21(2):155-64. PubMed ID: 6768490
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacodynamic effects of ethinyl estradiol in women using vaginal devices releasing small doses of levonorgestrel at a constant rate.
    Toddyvalla V; Johannisson E; Landgren BM; Cekan SZ; Diczfalusy E
    Contraception; 1983 Jul; 28(1):21-39. PubMed ID: 6414759
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pituitary and gonadal function during the use of progesterone- or progesterone-estradiol-releasing vaginal rings.
    Toivonen J
    Int J Fertil; 1980; 25(2):106-11. PubMed ID: 6117523
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ovarian function during use of a levonorgestrel-releasing IUD.
    Barbosa I; Bakos O; Olsson SE; Odlind V; Johansson ED
    Contraception; 1990 Jul; 42(1):51-66. PubMed ID: 2117516
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The response of the pituitary-ovarian axis to pulsatile administration of gonadotropin-releasing hormone in long-term oral contraceptive users.
    Hemrika DJ; Slaats EH; Schoemaker J
    Am J Obstet Gynecol; 1994 Feb; 170(2):462-8. PubMed ID: 8116698
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FSH and ovarian response: spontaneous recovery of pituitary-ovarian activity during the pill-free period vs. exogenous recombinant FSH during high-dose combined oral contraceptives.
    van Heusden AM; Coelingh Bennink HJ; Fauser BC
    Clin Endocrinol (Oxf); 2002 Apr; 56(4):509-17. PubMed ID: 11966744
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of ovulation by progestin analogs (agonists vs antagonists): preliminary evidence for different sites and mechanisms of actions.
    Heikinheimo O; Gordon K; Williams RF; Hodgen GD
    Contraception; 1996 Jan; 53(1):55-64. PubMed ID: 8631191
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of ethinyl estradiol 20 mcg and levonorgestrel 250 mcg on the pituitary-ovarian function during normal tablet-taking and when tablets are missed.
    Nuttall ID; Elstein M; McCafferty E; Seth J; Cameron ED
    Contraception; 1982 Aug; 26(2):121-35. PubMed ID: 6814817
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pituitary-ovarian relationships preceding the menopause. I. A cross-sectional study of serum follice-stimulating hormone, luteinizing hormone, prolactin, estradiol, and progesterone levels.
    Reyes FI; Winter JS; Faiman C
    Am J Obstet Gynecol; 1977 Nov; 129(5):557-64. PubMed ID: 910845
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Abnormal endocrine profile among women with confirmed or presumed ovulation during long-term Norplant use.
    Alvarez F; Brache V; Tejada AS; Faúndes A
    Contraception; 1986 Feb; 33(2):111-9. PubMed ID: 3084166
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasma hormone levels in women receiving new oral contraceptives containing ethinyl estradiol plus levonorgestrel or desogestrel.
    Gaspard UJ; Romus MA; Gillain D; Duvivier J; Demey-Ponsart E; Franchimont P
    Contraception; 1983 Jun; 27(6):577-90. PubMed ID: 6225622
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ovarian function is effectively inhibited by a low-dose triphasic oral contraceptive containing ethinylestradiol and levonorgestrel.
    Gaspard UJ; Dubois M; Gillain D; Franchimont P; Duvivier J
    Contraception; 1984 Apr; 29(4):305-18. PubMed ID: 6430638
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of a single contraceptive Silastic implant containing nomegestrol acetate on ovarian function and cervical mucus production during 2 years.
    Barbosa I; Coutinho E; Hirsch C; Ladipo O; Olsson SE; Ulmsten U
    Fertil Steril; 1996 Apr; 65(4):724-9. PubMed ID: 8654629
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pituitary, ovarian and endometrial effects of 300 micrograms norethisterone and 30 micrograms levonorgestrel administered on cycle days 7 to 10.
    Landgren BM; Dada O; Aedo AR; Johannisson E; Diczfalusy E
    Contraception; 1990 Jun; 41(6):569-81. PubMed ID: 2113848
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bleeding and ovulation control with use of a small contraceptive vaginal ring releasing levonorgestrel and estradiol.
    Toivonen J; Lähteenmäki P; Luukkainen T
    Contraception; 1979 Jul; 20(1):11-8. PubMed ID: 477313
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mode of action of dl-norgestrel and ethinylestradiol combination in postcoital contraception. II. Effect of postovulatory administration on ovarian function and endometrium.
    Ling WY; Wrixon W; Zayid I; Acorn T; Popat R; Wilson E
    Fertil Steril; 1983 Mar; 39(3):292-7. PubMed ID: 6402387
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The use of a contraceptive vaginal ring governed by the pattern of individual uterine bleeding.
    Toivonen J; Lähteenmäki P; Luukkainen T
    Contraception; 1979 Apr; 19(4):401-9. PubMed ID: 455988
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pulsatile luteinizing hormone patterns in long term oral contraceptive users.
    Hemrika DJ; Slaats EH; Kennedy JC; de Vries Robles-Korsen TJ; Schoemaker J
    J Clin Endocrinol Metab; 1993 Aug; 77(2):420-6. PubMed ID: 8345046
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fourteen-day versus twenty-one-day regimens of intermittent intranasal luteinizing hormone-releasing hormone agonist combined with an oral progestogen as antiovulatory contraceptive approach.
    Lemay A; Faure N
    J Clin Endocrinol Metab; 1986 Dec; 63(6):1379-85. PubMed ID: 2946711
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.